Total Revenue

14% decline (from $11.340K in Q1 2024 to $9.710K in Q1 2025)

Total revenue fell sharply as the decline in key segments—especially continuing weakness in PendoTECH-related orders—continued from prior periods, affecting both domestic and international streams. " "

Domestic Revenue

Declined from $6.190K in Q1 2024 to $5.583K in Q1 2025

Domestic sales dropped further due to persistent weakness in OEM orders (notably from PendoTECH), following trends of reduced domestic demand observed in previous periods. " "

Outside U.S. (OUS) Revenue

Dropped from $5.150K in Q1 2024 to $4.127K in Q1 2025

International revenue contracted more sharply, as ongoing challenges with distributors and regulatory delays from past periods worsened, leading to a steeper decline in key overseas markets. " "

Net Income

23% decline (from $3.956K in Q1 2024 to $3.041K in Q1 2025)

Net Income suffered due to lower revenues from the continued loss of major PendoTECH orders, coupled with a higher effective tax rate (increasing from 17.6% to 21.2% in Q1) and reduced non-operating income, intensifying prior trends. " "

Diluted EPS

15% decline (from $1.09 in Q1 2024 to $0.92 in Q1 2025)

EPS declined in line with lower net income, although the impact was partly softened by a smaller diluted share count from share repurchases—a strategy that had partially offset declines in previous periods. " "

Cash & Investments

11% decline (from $93.808K in Q1 2024 to $83.325K in Q1 2025)

Liquidity weakened as additional cash was used for share repurchases, dividends, and capital expenditures compared to the previous period, reflecting ongoing capital allocation strategies that have compressed cash balances. " "